Article metrics
PDF
Other content recommended for you
- The China Alzheimer Report 2022
- FDA’s dilemma with the aducanumab approval: public pressure and hope, surrogate markers and efficacy, and possible next steps
- Selecting the target population for new Alzheimer drugs: challenges and expectations
- Cognitive symptoms of Alzheimer’s disease: clinical management and prevention
- MRI and cerebrospinal fluid biomarkers for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: a diagnostic accuracy study
- How many patients are eligible for disease-modifying treatment in Alzheimer’s disease? A French national observational study over 5 years
- Novel drug candidates targeting Alzheimer’s disease: ethical challenges with identifying the relevant patient population
- Safety and efficacy of plasma transfusion from exercise-trained donors in patients with early Alzheimer’s disease: protocol for the ExPlas study
- On the personal utility of Alzheimer’s disease-related biomarker testing in the research context
- Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer’s disease: a focused review on recent advances